Localized Renal Cell Carcinoma
Advertisement
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
The retrospective study sought to determine if surgery would benefit patients and identify prognostic factors.
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
New data compares renal function outcomes of SABR in patients with solitary versus bilateral kidneys.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.